Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 28, 2017 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of Sunesis, will present at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 8:40 AM Eastern Time at The Westin Grand Central in New York City.
A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older, as well as advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717
